Kayne Anderson Rudnick Investment Management
CRL icon

Kayne Anderson Rudnick Investment Management’s Charles River Laboratories CRL Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.1K Sell
79
-1
-1% -$178 ﹤0.01% 697
2026
Q1 		$13.9K Sell
80
-10
-11% -$1.85K ﹤0.01% 667
2025
Q4 		$18.1K Hold
90
– – ﹤0.01% 673
2025
Q3 		$14.1K Hold
90
– – ﹤0.01% 694
2025
Q2 		$13.7K Sell
90
-1,950,183
-100% -$260M ﹤0.01% 698
2025
Q1 		$294M Buy
1,950,273
+144,732
+8% +$24.3M 0.72% 49
2024
Q4 		$333M Sell
1,805,541
-134,284
-7% -$25.9M 0.77% 49
2024
Q3 		$382M Buy
1,939,825
+30,836
+2% +$6.41M 0.84% 45
2024
Q2 		$394M Buy
1,908,989
+31,359
+2% +$7.11M 0.96% 38
2024
Q1 		$509M Buy
1,877,630
+124,392
+7% +$29.7M 1.18% 26
2023
Q4 		$414M Buy
1,753,238
+7,137
+0.4% +$1.4M 1.04% 35
2023
Q3 		$342M Buy
1,746,101
+64,981
+4% +$13.3M 0.98% 38
2023
Q2 		$353M Buy
1,681,120
+52,757
+3% +$10.5M 0.99% 36
2023
Q1 		$329M Buy
1,628,363
+11,563
+0.7% +$2.62M 0.97% 39
2022
Q4 		$352M Sell
1,616,800
-15,461
-0.9% -$3.38M 1.1% 33
2022
Q3 		$321M Buy
1,632,261
+22,434
+1% +$4.84M 1.07% 30
2022
Q2 		$344M Sell
1,609,827
-28,856
-2% -$7.05M 1.09% 30
2022
Q1 		$465M Buy
1,638,683
+86,028
+6% +$26.5M 1.24% 24
2021
Q4 		$585M Buy
1,552,655
+70,850
+5% +$27.5M 1.35% 16
2021
Q3 		$611M Buy
1,481,805
+84,769
+6% +$35.2M 1.48% 10
2021
Q2 		$517M Buy
1,397,036
+135,717
+11% +$45.3M 1.27% 19
2021
Q1 		$366M Buy
1,261,319
+169,486
+16% +$47.1M 0.98% 30
2020
Q4 		$273M Buy
1,091,833
+145,362
+15% +$34.6M 0.79% 45
2020
Q3 		$214M Buy
946,471
+153,828
+19% +$31.9M 0.78% 42
2020
Q2 		$138M Buy
792,643
+145,047
+22% +$23.1M 0.58% 52
2020
Q1 		$81.7M Sell
647,596
-565,314
-47% -$84.8M 0.47% 62
2019
Q4 		$185M Buy
1,212,910
+87,523
+8% +$12.1M 0.89% 32
2019
Q3 		$149M Buy
1,125,387
+667,611
+146% +$89.5M 0.78% 38
2019
Q2 		$65M Buy
457,776
+112,229
+32% +$15.2M 0.34% 74
2019
Q1 		$50.2M Buy
345,547
+44,718
+15% +$5.88M 0.29% 82
2018
Q4 		$34M Sell
300,829
-4,489
-1% -$562K 0.23% 90
2018
Q3 		$41.1M Buy
+305,318
New +$37.7M 0.24% 90

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's CRL Position: Q2 2026 in Review

Kayne Anderson Rudnick Investment Management reduced its Charles River Laboratories (CRL) stake by 1.3% in Q2 2026, selling an estimated $178 and leaving 79 shares worth $18.1K. The position accounts for ﹤0.01% of the portfolio, ranked #697.

Kayne Anderson Rudnick Investment Management first reported a position in CRL in Q3 2018 and has held it in 32 quarters since. The position peaked at $611M in Q3 2021. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Kayne Anderson Rudnick Investment Management held 79 shares of Charles River Laboratories worth $18.1K as of Q2 2026.
  • Kayne Anderson Rudnick Investment Management sold 1 Charles River Laboratories share in Q2 2026, an estimated $178.
  • Charles River Laboratories made up ﹤0.01% of Kayne Anderson Rudnick Investment Management's portfolio in Q2 2026, its #697 holding.
  • Kayne Anderson Rudnick Investment Management first reported a position in Charles River Laboratories in Q3 2018 and has held it in 32 quarters since.
  • Kayne Anderson Rudnick Investment Management's Charles River Laboratories position peaked at $611M in Q3 2021.
  • 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.